Adalimumab biosimilar - Samsung Bioepis

Drug Profile

Adalimumab biosimilar - Samsung Bioepis

Alternative Names: Imraldi; SB-5

Latest Information Update: 27 Jun 2017

Price : $50

At a glance

  • Originator Samsung Bioepis
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Ankylosing spondylitis; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis; Ulcerative colitis; Uveitis

Most Recent Events

  • 23 Jun 2017 Biogen receives a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the EMA for adalimumab biosimilar referencing Humira®
  • 11 Nov 2016 Updated efficacy and adverse events data from a phase III trial in Rheumatoid Arthritis presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
  • 17 Jul 2016 Preregistration for Rheumatoid arthritis (In the elderly, In adults) in European Union (SC) before July 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top